Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Review Article and Clinical Experience: DIABETES MELLITUS AND ENDOTHELIAL DYSFUNCTION: A CLINICAL APPROACH (Molecular Basis for Clinical Application)

Folia Medica Indonesiana · Vol. 39 No. 3 (2003)

ISSN
2355-8393, 2599-056X
Terbit
2003-07-01
Penerbit
Airlangga University
Bahasa
en

Abstrak

SYNDROME-36 (presented in the year 2002) compiled by the Author since 1992 (SYNDROME-11) represents a cluster of 36 components (comprises Risk & Protective Factors, and Predictors), which determines the quality of Endothelial Function. The most frequent causes of Endothelial Dysfunction (ED) are Hypertension, Diabetes Mellitus, and Lipid (Dyslipidemia) which can be abbreviated as HDL-Syndrome. In clinical practice, cigarette should be included as a major risk factor in the pathogenesis of atherosclerosis ( HDL-C Syndrome ). Four functional targets for the quality of the Endothelial Cell function are 1. Lumen (Vasoconstrictors ET-1, and Vasodilators NO, Bradykinin, Hyperpolarizing Factor), 2. Growth (Stimulators PDGF, ET, All, and Inhibitors NO, PG12, TGF), 3. Inflammation (Proinflammatory Adhesion Molecules, and Anti Inflammatory), and 4. Hemostasis (Prothrombotic PAI-1, and Anti Thrombotic PG12, tPA). The Endothelial Cell produces mediators that induce vasoconstriction, including ET (Endothelin), Prostaglandins (PGG2 and PGH2), and Angiotensin-11 (AII). The key enzyme that regulates the local generation of AII is Angiotensin Converting Enzyme (ACE). Angiotensin-II also stimulates the generation of Superoxide. Nitric Oxide (NO) is not only involved in the control of vasomotor tone, but also in vascular homeostasis and immunological functions; eleven (11) roles of NO as atheroprotector of Endothelial Dysfunction have been summarized by the author. The five principles of thetreatment of ED esp. in Diabetes Mellitus are 1. Insulin Sensitizer (in DM excellent glycemic control is obligatory), 2. ACEinhibitors (Tissue ACE-IS Quinapril etc), 3. Lipid Modulators (Statins Atorvastatin etc, and or Fibrates), 4. Antioxidants (Raxofelast 600 mg bid, Vit. C 500 mg/day, Vit. E 400-800 mg/day, Beta Carotene), and 5. Arginine Supplementation (Diet-KV, tablet Arginine 450 mg/day). Diet-KV comprises 68% cal. Cbh, 12% cal. Protein, 20% cal. Fat (Cholesterol < 300 mg/day), Fiber ± 35 g/day, Enriched with food supplements containing Arginine, Folate, Vit. B6, and Vit. B12. Several studies, fe. TREND (1996), BANFF (2000) have established that a potent tissue ACE-I (Quinapril) improves Endothelial Function in humans. Interestingly, the BANFF study showed this anti hypertensive agent from other classes has no effect on Endothelial Function. These results are strengthened by those from QUO VADIS (2000). In this study the treatment with Quinapril significantly reduced clinical ischemic events during the one-year period after coronary bypass graft surgery. The rank order of potency of several different ACE inhibitors have been determined by several investigators as follows (by sequent numbers) 1. Quinapril = Benazepril, 2. Ramipril, 3. Perindopril, 4. Lisinopril, 5. Enalapril, 6. Fosinopril, and 7. Captopril. Conclusion Endothelial Dysfunction (ED) has been widely documented in patients with Diabetes Mellitus and more frequently in those with HDL Syndrome. Five principles of treatment of ED are summarized. Tissue-ACE-IS (Quinapril is the most potent one) play pivotal roles in the improvement of ED and these lines of evidence are strengthened by the results of TREND, BANFF, and QUO VADIS studies.

Kata kunci

Jaringan kolaborasi para penulis

8 penulis · 16 tautan kepenulisan bersama · 7 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universitas Airlangga
  • University of Brawijaya
  • Rumah Sakit Umum Pusat Dr. Sardjito
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Agung Sindu PranotoUniversitas Airlangga1
Hermina NovidaUniversitas Airlangga1
Jongky Hendro PrayitnoAfiliasi tidak diketahui1
Adeodatus Yuda HandayaRumah Sakit Umum Pusat Dr. Sardjito1
Djanggan SargowoUniversity of Brawijaya1
Diana LyrawatiUniversity of Brawijaya1
Mohammad Aris WidodoUniversity of Brawijaya1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210179714, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Review Article and Clinical Experience: DIABETES MELLITUS AND ENDOTHELIAL DYSFUNCTION: A CLINICAL APPROACH (Molecular Basis for Clinical Application)</dc:title><dc:creator>Askandar Tjokroprawiro</dc:creator><dc:subject>endothelial dysfunction</dc:subject><dc:subject>diabetes mellitus</dc:subject><dc:subject>endothelial function</dc:subject><dc:subject>hypertension</dc:subject><dc:subject>dyslipidemia</dc:subject><dc:subject>atherosclerosis</dc:subject><dc:subject>nitric oxide</dc:subject><dc:subject>endothelin</dc:subject><dc:subject>angiotensin II</dc:subject><dc:subject>ACE inhibitors</dc:subject><dc:subject>statins</dc:subject><dc:subject>fibrates</dc:subject><dc:subject>antioxidants</dc:subject><dc:subject>insulin sensitizers</dc:subject><dc:subject>endothelial inflammation</dc:subject><dc:subject>hemostasis</dc:subject><dc:subject>endothelial growth factor</dc:subject><dc:subject>risk factors</dc:subject><dc:description xml:lang="en">SYNDROME-36 (presented in the year 2002) compiled by the Author since 1992 (SYNDROME-11) represents a cluster of 36 components (comprises Risk &amp; Protective Factors, and Predictors), which determines the quality of Endothelial Function. The most frequent causes of Endothelial Dysfunction (ED) are Hypertension, Diabetes Mellitus, and Lipid (Dyslipidemia) which can be abbreviated as HDL-Syndrome . In clinical practice, cigarette should be included as a major risk factor in the pathogenesis of atherosclerosis ( HDL-C Syndrome ). Four functional targets for the quality of the Endothelial Cell function are 1. Lumen (Vasoconstrictors ET-1, and Vasodilators NO, Bradykinin, Hyperpolarizing Factor), 2. Growth (Stimulators PDGF, ET, All, and Inhibitors NO, PG12, TGF), 3. Inflammation (Proinflammatory Adhesion Molecules, and Anti Inflammatory), and 4. Hemostasis (Prothrombotic PAI-1, and Anti Thrombotic PG12, tPA). The Endothelial Cell produces mediators that induce vasoconstriction, including ET (Endothelin), Prostaglandins (PGG2 and PGH2), and Angiotensin-11 (AII). The key enzyme that regulates the local generation of AII is Angiotensin Converting Enzyme (ACE). Angiotensin-II also stimulates the generation of Superoxide. Nitric Oxide (NO) is not only involved in the control of vasomotor tone, but also in vascular homeostasis and immunological functions; eleven (11) roles of NO as atheroprotector of Endothelial Dysfunction have been summarized by the author. The five principles of thetreatment of ED esp. in Diabetes Mellitus are 1. Insulin Sensitizer (in DM excellent glycemic control is obligatory), 2. ACEinhibitors (Tissue ACE-IS Quinapril etc), 3. Lipid Modulators (Statins Atorvastatin etc, and or Fibrates), 4. Antioxidants (Raxofelast 600 mg bid, Vit. C 500 mg/day, Vit. E 400-800 mg/day, Beta Carotene), and 5. Arginine Supplementation (Diet-KV, tablet Arginine 450 mg/day). Diet-KV comprises 68% cal. Cbh, 12% cal. Protein, 20% cal. Fat (Cholesterol &lt; 300 mg/day), Fiber ± 35 g/day, Enriched with food supplements containing Arginine, Folate, Vit. B6, and Vit. B12. Several studies, fe. TREND (1996), BANFF (2000) have established that a potent tissue ACE-I (Quinapril) improves Endothelial Function in humans. Interestingly, the BANFF study showed this anti hypertensive agent from other classes has no effect on Endothelial Function. These results are strengthened by those from QUO VADIS (2000). In this study the treatment with Quinapril significantly reduced clinical ischemic events during the one-year period after coronary bypass graft surgery. The rank order of potency of several different ACE inhibitors have been determined by several investigators as follows (by sequent numbers) 1. Quinapril = Benazepril, 2. Ramipril, 3. Perindopril, 4. Lisinopril, 5. Enalapril, 6. Fosinopril, and 7. Captopril. Conclusion Endothelial Dysfunction (ED) has been widely documented in patients with Diabetes Mellitus and more frequently in those with HDL Syndrome . Five principles of treatment of ED are summarized. Tissue-ACE-IS (Quinapril is the most potent one) play pivotal roles in the improvement of ED and these lines of evidence are strengthened by the results of TREND, BANFF, and QUO VADIS studies.</dc:description><dc:publisher>Airlangga University</dc:publisher><dc:date>2003-07-01</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>http://journal.unair.ac.id/filerPDF/abstrak_13383_tpjua.pdf</dc:identifier><dc:source>Folia Medica Indonesiana; Vol 39 No 3 (2003)</dc:source><dc:source>2355-8393</dc:source><dc:source>2599-056X</dc:source><dc:language>en</dc:language></oai_dc:dc>